Pipeline Progress at Endocyte - Analyst Blog

By
A A A

Endocyte Inc. ( ECYT ) recently announced that its oncology candidate, EC0652, achieved key objectives in a phase 0 study. Endocyte is developing the candidate as a treatment of patients suffering from prostate cancer.

EC0652 is a diagnostic imaging agent that targets prostate specific membrane antigen (PSMA), a protein expressed on cancer cells which originates from the prostate as well as on tumor neovasculature.

Endocyte also has plans to advance its corresponding therapeutic agent, EC1069. EC1069 is a proprietary PSMA-targeted small molecule drug conjugate (SMDC) linked with the anti-cancer drug tubulysin. Endocyte plans to file an Investigational New Drug (IND) application for EC1069 by the end of this year.

Meanwhile, the company's focus remains on its oncology candidate, vintafolide (MK-8109/EC145). Last year, the company submitted a marketing authorization application (MAA) for the candidate in the EU. Endocyte is also looking for EU approval of an investigational companion diagnostic imaging agent etarfolatide (EC20) along with vintafolide. Both the candidates were granted orphan drug status in the EU.

Endocyte and its partner, Merck & Co. Inc. ( MRK ), are looking to get vintafolide approved as a treatment of patients suffering from folate-receptor positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin (PLD).

We remind investors that the oncology market is extremely competitive with the presence of companies like Roche Holding ( RHHBY ).

We expect investor focus to remain on the European Medicine Agency's decision regarding the approval of vintafolide and etarfolatide.

Endocyte carries a Zacks Rank #3 (Hold). However, Valeant Pharmaceuticals International Inc. ( VRX ), currently looks more attractive in the pharma sector with a Zacks Rank #1 (Strong Buy).



ENDOCYTE INC (ECYT): Free Stock Analysis Report

MERCK & CO INC (MRK): Free Stock Analysis Report

(RHHBY): ETF Research Reports

VALEANT PHARMA (VRX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ECYT , IND , MAA , MRK , PLD

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

31,945,821
  • $75.38 ▲ 0.53%
26,050,704
  • $97.43 ▲ 0.41%
24,766,975
  • $3.755 ▲ 0.67%
22,162,949
  • $3.431 ▼ 0.55%
19,985,583
  • $25.21 ▼ 12.22%
18,958,851
  • $34.975 ▼ 2.14%
18,264,219
  • $15.60 ▼ 0.13%
17,513,174
  • $10.88 ▲ 3.32%
As of 7/25/2014, 01:09 PM